Loading...
Docoh

Nymox Pharmaceutical (NYMX)

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

NYMX stock data

Calendar

30 Mar 22
12 Aug 22
31 Dec 22
Quarter (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 May 22 Robinson James George Common Stock Buy Acquire P No No 1.65 1,151,515 1.9M 4,702,065
2 May 22 Robinson James George Warrant Common stock Buy Acquire P No No 2 1,151,515 2.3M 1,151,515
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.085 200 417 3,550,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0882 1,100 2.3K 3,550,350
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0899 2,900 6.06K 3,549,250
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.1 800 1.68K 3,546,350
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.08 51 106.08 3,545,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0899 4,949 10.34K 3,545,499
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.05 5,000 10.25K 3,540,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.105 3,100 6.53K 3,535,550
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Competition
Quest DiagnosticsOrasure

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: alter, anniversary, Aveback, communicated, communicating, communication, concurrent, Culter, customary, exemplary, ID, issuable, reclassified, reward, thousand
Removed: waived
Proxies
No filings

Patents

Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
21 Jul 22
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
Utility
Focal treatment of prostate cancer
17 May 22
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
Utility
Method of treating lower urinary tract symptoms with fexapotide triflutate
22 Mar 22
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
Utility
Methods of treating multifocal cancer
25 Jan 22
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.